Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078420 | 0.79 | MEN1 (0.46) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL11040986 | 0.77 | MEN1 (0.44) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL2354190 | 0.74 | LMNA (0.41) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL13562892 | 0.72 | MAOB (0.48) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL8845592 | 0.72 | MEN1 (0.42) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL23532475 | 0.72 | MEN1 (0.37) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL10895446 | 0.69 | MEN1 (0.42) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL11374909 | 0.69 | OPRM1 (0.39) | MEN1KMT2AMAOBMAOAOPRM1 | |
| SCHEMBL4089154 | 0.69 | CA1 (0.48) | MAOBMAOAOPRM1OPRL1GRIN1 | |
| SCHEMBL2969527 | 0.69 | OPRM1 (0.44) | MEN1KMT2AMAOBMAOAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | SQLE, C9, PHOSPHO1 | MEN1 460/4885KMT2A 2194/4885MAOB 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.